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Abstract
Background: The driver mutations JAK2V617F, MPLW515L/K and CALR influence disease phenotype of
myeloproliferative neoplasms (MPNs) and might sustain a condition of chronic inflammation. Pentraxin 3 (PTX3) and
high-sensitivity C-reactive protein (hs-CRP) are inflammatory biomarkers potentially useful for refining prognostic
classification of MPNs.
Methods: We evaluated 305 with essential thrombocythemia (ET) and 172 polycythemia vera (PV) patients
diagnosed according to the 2016 WHO criteria and with full molecular characterization for driver mutations.
Results: PTX3 levels were significantly increased in carriers of homozygous JAK2V617F mutation compared to all the
other genotypes and triple negative ET patients, while hs-CRP levels were independent of the mutational profile. The risk
of haematological evolution and death from any cause was about 2- and 1.5-fold increased in individuals with high PTX-3
levels, while the thrombosis rate tended to be lower. High hs-CRP levels were associated with risk of haematological
evolution, death and also major thrombosis. After sequential adjustment for potential confounders (age, gender, diagnosis
and treatments) and the presence of JAK2V617F homozygous status, high hs-CRP levels remained significant for all
outcomes, while JAK2V617F homozygous status as well as treatments were the factors independently accounting for
adverse outcomes among patients with high PTX3 levels.
Conclusions: These results provide evidence that JAK2V617F mutation influences MPN-associated inflammation with a
strong correlation between allele burden and PTX3 levels. Plasma levels of hs-CRP and PTX3 might be of prognostic value
for patients with ET and PV, but their validation in future prospective studies is needed.
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Background
Polycythemia vera (PV) and essential thrombocythemia
(ET) are chronic myeloproliferative neoplasms (MPNs)
characterized by clonal expansion of an abnormal haem-
atopoietic progenitor cell and a clinical course that is
complicated by frequent cardiovascular complications as
well as increased risk of transformation to myelofibrosis
(MF) or acute leukaemia (AL) [1, 2]. The discovery of
the Janus kinase 2 (JAK2) V617F mutation significantly
improved the understanding of the biology of these disor-
ders [3]. The subsequent identification of other acquired
somatic lesions, such as JAK2 exon 12 mutation [4], muta-
tion in the gene encoding thrombopoietin receptor
(MPLW515L/K) [5] and the recently discovered mutations
in the exon 9 of calreticulin (CALR) gene [6, 7] reinforced
the central role of cytokine receptor/signal transduction
lesions in promoting MPN phenotypes. In surveys of large
MPN cohorts, JAK2V617F can be detected in 95% of pa-
tients with PV and JAK2 exon12 mutation in the
remaining 5% of patients. Among ET patients, JAK2V617F
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can be detected in 60 to 65% of patients, MPLW515L/K
in about 5% and CALR mutation in about 20 to 25%. The
understanding that an array of somatic mutations contrib-
utes to the biology of these disorders [8, 9] prompted new
studies to address the impact of patients’ mutation back-
ground on disease phenotype. These studies demonstrated
that somatic mutations, by determining a more pro-
nounced activation of platelets, leukocytes and endothelial
cells [10, 11] and promoting an increased number of leu-
kocytes [12] can sustain a condition of chronic inflamma-
tion, which may contribute not only to the premature
atherosclerosis underlying the cardiovascular events but
also to clonal evolution and second cancer [2, 13–17].
Based on these data, there is an increasing interest in two
inflammatory biomarkers, belonging to the superfamily of
pentraxins, such as pentraxin 3 (PTX3) and high-
sensitivity C-reactive protein (hs-CRP). We hypothesized
that these inflammatory markers might be useful to im-
prove prognostic classification of patients with ET and PV.
In a previous paper, we showed that PTX3 and hs-CRP
levels were correlated with JAK2 mutation allelic burden
and associated with different risks of thrombosis, although
in opposite directions [18]. Furthermore, elevated hs-CRP
levels were associated with shortened leukaemia-free sur-
vival (LFS) in myelofibrosis [19]. However, whether or not
somatic mutations, other than JAK2V617F, influence the
blood levels of PTX3 and hs-CRP is unknown and their
association with the main incident relevant outcomes in
ET and PV patients has not been fully explored. Accord-
ingly, in this cross-sectional study, we examined a large
cohort of patients with PV and ET.
Methods
Blood samples of 477 patients with ET and PV, diagnosed
according to the 2016 World Health Organization
(WHO) criteria [20], were obtained from consecutive,
well-characterized patients, regularly followed in two Ital-
ian haematological centers (Bergamo and Florence). Insti-
tutional review board approval was obtained from the two
participating centres in the framework of the AIRC-
Gruppo Italiano Malattie Mieloproliferative (AGIMM)
project. Blood samples were obtained at diagnosis in 172
patients (36%) or during follow-up in 306 (64%) (median
time from diagnosis was 4.2 years, range 0.03–29.8 years).
The following previously published methods were used:
real-time quantitative PCR for JAK2V617F [21] and high-
resolution melting analysis followed by bidirectional
Sanger sequencing or next-generation sequencing for
MPLW515L/K and CALR mutations [22]. In particular,
evaluation of JAK2V617F mutation was performed on the
genomic DNA purified from granulocytes by qualitative
or quantitative method. Qualitative assay was based on a
allele-specific PCR starting from 100 ng DNA with a sen-
sitivity defined as 0.5–2% [23]. Quantitative assay for the
measurement of JAK2V617F allele burden was performed
by a quantitative real-time PCR assay, using 40 ng DNA.
All samples were analysed in triplicate, and the amount of
JAK2V617F allele was calculated by comparison with ser-
ial dilutions of JAK2 plasmids. The sensitivity of the quan-
titative method is 0.08–0.008% [21]. JAK2V617F mutation
was classified as having low allele burden (<50%, heterozy-
gous) or high allele burden (≥50%, homozygous). High-
sensitivity C-reactive protein (hs-CRP) was measured by a
latex immunoassay (CardioPhaseHigh Sensitivity Siemens
Healthcare Diagnostic Inc., Italy) and PTX3 plasma levels
were measured by an in-house Sandwich ELISA as previ-
ously described [18].
Major outcomes recorded anytime during the follow-up
period were major thrombosis, bleeding, evolution to MF
or AL and death. Patients were treated according to
current recommendations [24] and therapy included phle-
botomy, hydroxyurea, pipobroman, busulfan and alpha
interferon. Evolution to post-ET and post-PV MF and AL
was diagnosed following the International Working Group
for Myeloproliferative Neoplasms Research and Treat-
ment and WHO criteria, respectively [20, 25].
Statistical analysis
Continuous values were expressed as medians and
ranges, and nonparametric K-sample test on the equality
of medians was used to test the null hypothesis that the
K samples were drawn from populations with the same
median. Categorical data were given as counts and per-
centages; chi-square or Fisher exact test was used to test
independence between groups, as appropriate. Boxplots
were used to graph distributions across mutational
groups. Statistical difference in means of hs-CRP and
PTX3 values among mutations was tested considering
JAK2V617F homozygous category as reference. Bonfer-
roni correction was used to adjust the probability (p)
values because of the increased risk of the type I error
when making multiple statistical tests. Incidence rate of
outcomes of interest (major thrombosis, bleeding, haem-
atological evolution and death) were expressed as % pa-
tients/year. Logistic regression models were applied to
estimate risk prediction of inflammatory biomarkers on
outcomes. Multivariable models were evaluated un-
adjusted and sequentially adjusted for potential confound-
ing factors. All tests for statistical significance were two-
tailed and a value of p < 0.05 was chosen as the cut-off
level for statistical significance. The statistical package
STATA for Windows version 12 was used for analysis.
Results
General characteristics of the whole population
The 477 patients included 305 with ET (median age 58
years; 63% females) and 172 with PV (median age 58
years; 47% females). Presenting features of the study
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population are shown in Table 1. Among 305 ET pa-
tients, JAK2V617F, MPLW515L/K and CALR mutations
were detected in 190 (63%), 14 (5%) and 44 (14%), re-
spectively. The remaining 57 patients (18%) were wild
type for all three mutations (triple negative). The group
of PV included 95 (55%) patients with heterozygous
JAK2V617F mutation, 64 (37%) with homozygous
JAK2V617F mutation, 4 (2%) with JAK2 exon 12 muta-
tion and 9 (5%) with non-mutated JAK2. Median follow-
up from diagnosis was 5.4 (range 0.01–30.7) and 6.4
(0.01–30) years in ET and PV, respectively. Aspirin was
prescribed in the majority of cases and cytoreductive
treatments were given in 57% and 64% of ET and PV
cases, respectively. The 306 patients for whom blood
samples were obtained during follow-up were receiving
antiplatelet agents in the 77 and 60% and cytoreductive
treatments in 65 and 68% of ET and PV cases, respect-
ively. The majority of cytoreductive treatments used in
this group of patients was hydroxyurea. In all cohorts,
none of the patients was in treatment with glucocorti-
coids at the moment of blood sample collection, while
only a minority was receiving statins as usual therapy.
Driver mutations and PTX3 and hs-CRP values distribution
The median circulating plasma levels of PTX3 detected
in ET and PV were similar, being respectively 4.55 ng/
mL, range 0.58–14.95 and 5.88 ng/mL, range 0.42–23.
Similarly, the median circulating plasma levels of hs-
CRP were 0.83 mg/L, range 0.03–7.96 in ET and 0.87
mg/L, range 0.03–6.43 in PV (Table 1). There was no
correlation between hs-CRP and PTX3 both in PV and
ET (r = −0.089, p = 0.29 and r = 0.027, p = 0.64, respect-
ively). In ET patients, hs-CRP levels were similar in
triple negative and carriers of CALR, MPLW515L/K,
heterozygous JAK2V617F or homozygous JAK2V617F
mutations. In contrast, the circulating levels of PTX3
were significantly increased in homozygous JAK2V617F
mutation carriers compared to all the other genotypes
(Fig. 1). Interestingly, also for PV patients, we observed
significantly greater PTX3 blood levels in homozygous
JAK2V617F mutation carriers compared to heterozy-
gous, while hs-CRP levels were not different by muta-
tional status (Fig. 1). To exclude that the association
between PTX3 and JAK2V617F homozygous mutation
could be affected by other risk factors, we tested whether
this relationship remained statistically significant after ad-
justment for diagnosis (PV vs. ET), gender, age and muta-
tions (JAK2V617F homozygous vs. other mutations) in a
multivariate model. This analysis confirmed a significant
association only between JAK2V617F homozygous status
and high levels of PTX-3 only (odds ratio (OR) 1.93, 95%
confidence interval (CI) 1.44–2.59, p < 0.0001).
Clinical outcomes according to mutational status and hs-
CRP and PTX3 values
Fifty-five major thrombotic events occurring during
follow-up were registered. Thirty major thrombotic events
were registered before blood sampling. The rate of throm-
bosis was 2.44% patients/year (95% CI 1.35–4.41).
Hemorrhagic events were observed during follow-up in a
total of 43 patients (9%); the total rate of bleeding was of
1.25 patients/year (95% CI 0.93–1.69). A total of 33 cases
of transformation to MF or AL were documented (28 to
MF and 5 to AL), accounting for an estimated incidence
of haematological transformation of 0.94% patients/year
(95% CI 0.66–1.33). The rate of transformation was 0.57%
patients/year (95% CI 0.32–1.00) and 1.56% patients/year
(95% CI 1.01–2.41) in ET and PV patients, respectively.
Table 1 Patients’ characteristics
ET PV Total
N, (%) 305 (64) 172 (36) 477
Sex (M/F), n (%) 112/193 (37/63) 91/81 (53/47) 203/274 (43/57)
Age, years,
median (5th–95th percentiles)
58.0 (27.7–83.0) 58.3 (35.5–82.0) 58.0 (28.3–82.7)
Mutational status, n (%)
Triple negatives 57 (18) 9 (5) 66 (14)
CALR 44 (14) 0 (0) 44 (9)
MPLW515L/K 14 (5) 0 (0) 14 (3)
JAK2V617F hetero 176 (58) 95 (55) 271 (57)
JAK2V617F homo 14 (5) 64 (37) 78 (16)
JAK2 exon 12 mutation 0 (0) 4 (2) 4 (1)
Hs-CRP, mg/L,
median (5th–95th percentiles)
0.83 (0.03–7.96) 0.87 (0.03–6.43) 0.83 (0.03–7.53)
PTX3, ng/mL,
median (5th–95th percentiles)
4.55 (0.58–14.95) 5.88 (0.42–22.96) 4.83 (0.54–18.48)
ET essential thrombocythemia, PV polycythemia vera, hetero heterozygous, homo homozygous
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Among patients taking cytoreductive therapy, the inci-
dence of haematological transformation was 1.19% pa-
tients/year (95% CI 0.83–1.71) as opposed to 0.31%
(95% CI 0.10–0.93) of patients without cytoreductive
treatment. The percentage of transformation among 57
triple negative and 248 mutated ET was 0.36% patients/
year (95% CI 0.05–2.54) and 0.99% patients/year (95%
CI 0.69–1.41), respectively.
During the time of this study, there were 56 deaths ac-
counting for a mortality rate of 1.58% patients/year (95%
CI 1.22–2.06).
To test the hypothesis that different levels of hs-CRP
and PTX3 are associated with different outcomes, we
categorized PTX3 and hs-CRP using their respective
50th percentile of distribution in the whole cohort as
cut-off point and, accordingly, we divided the study co-
hort in high level group for values above the 50th per-
centile and reference group for values below the 50th
percentile. Clinical outcomes associated with high levels
of PTX3 and hs-CRP are presented in Table 2. The
crude relative risk for haematological evolution and
death associated with PTX3 levels above the 50th per-
centile (≥4.8 ng/ml) were 1.84 (95% CI, 1.02–3.96) and
1.58 (95% CI, 1.10–2.84), respectively. The multivariable
analysis, after sequential adjustment for diagnosis (PV
vs. ET), gender, age, treatments (cytoreductive treat-
ments and antiplatelet agents) and mutations showed
that the main factor accounting for the excess of haem-
atological evolution and deaths was the presence of
JAK2V617F homozygous status, as well as the need of
treatments (Table 2). In contrast, high levels of PTX3
were associated with a trend to a lower risk of thrombosis
also after adjustment for JAK2V617F mutation (OR 0.57,
95% CI 0.31–1.04), suggesting a possible protective effect
of PTX3. In patients with high hs-CRP levels (>50th per-
centile, ≥0.8 mg/L) the risk of haematological evolution
Fig. 1 Hs-CRP (a) and PTX-3 (b) values distribution according to disease and mutational status. Boxplot graphs. Analysis of multiple contrasts
versus JAK2V617F homozygous as reference category (Bonferroni adjustment). Only p value less than 0.05 are quoted
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and death were significantly increased compared to refer-
ence group (OR 2.70, 95% CI 1.23–5.95 and OR 3.93, 95%
CI 2.01–7.68, respectively). Moreover, patients in the high
hs-CRP group suffered also from an excess of thrombosis
(OR 2.57, 95% CI 1.39–4.75). It is worth noting that hs-
CRP proved an independent risk factor for adverse events
in sequential multivariate analysis, also after adjustment for
JAK2V617F high allele burden (Table 2). Patients in the
high PTX3 or hs-CRP group showed a similar risk of bleed-
ing compared to reference groups (OR 1.07, 95% CI 0.57–
2.02 and OR 0.77, 95% CI 0.41–1.45, respectively) (Table 2).
Discussion
This paper conducted on a large population of ET and PV
patients shows a strong association between the levels of
PTX3 and JAK2V617F allele burden and also indicate that
Table 2 Unadjusted and sequentially multivariable adjusted risk of principal outcomes in ET and PV patients associated to hs-CRP
and PTX-3 values over their respective medians
Hs-CRP ≥0.8 mg/La PTX-3 ≥4.8 ng/mLa
OR 95% CI p OR 95% CI p
Thrombosis (n = 55)
Unadjusted 2.57 1.39–4.75 0.003 0.66 0.37–1.16 0.145
Adjusted for
+ Male sex 2.57 1.39–4.75 0.003 0.66 0.37–1.16 0.146
+ Age at diagnosis 2.56 1.38–4.73 0.003 0.65 0.37–1.15 0.139
+ PV disease 2.59 1.40–4.81 0.003 0.60 0.34–1.07 0.085
+ Cytoreduction + antiplatelet agents 2.60 1.37–4.95 0.003 0.57 0.31–1.04 0.068
+ JAK2V617F homo 2.60 1.37–4.95 0.003 0.57 0.31–1.04 0.066
Bleeding (n = 43)
Unadjusted 0.77 0.41–1.45 0.419 1.07 0.57–2.02 0.831
Adjusted for
+ Male sex 0.77 0.41–1.46 0.428 1.07 0.57–2.01 0.842
+ Age at diagnosis 0.84 0.44–1.61 0.596 1.06 0.56–2.01 0.864
+ PV disease 0.84 0.44–1.62 0.603 0.97 0.50–1.86 0.920
+ Cytoreduction+
antiplatelet agents
0.82 0.43–1.59 0.557 0.95 0.49–1.84 0.883
+ JAK2V617F homo 0.83 0.43–1.60 0.574 0.92 0.48–1.79 0.815
Haematological evolution (n = 33)
Unadjusted 2.70 1.23–5.95 0.013 1.84 1.02–3.96 0.044
Adjusted for
+ Male sex 2.66 1.20–5.86 0.015 1.87 1.02–3.99 0.042
+ Age at diagnosis 2.61 1.18–2.88 0.018 1.84 1.01–3.98 0.046
+ PV disease 2.70 1.21–6.01 0.015 1.59 0.72–3.48 0.251
+ Cytoreduction + antiplatelet agents 2.72 1.21–6.15 0.016 1.64 0.74–3.63 0.225
+ JAK2V617F homo 2.79 1.23–6.32 0.014 1.55 0.69–3.46 0.286
Death (n = 56)
Unadjusted 3.93 2.01–7.68 <.0001 1.58 1.10–2.84 0.039
Adjusted for
+ Male sex 3.86 1.98–7.55 <.0001 1.61 1.09–2.85 0.041
+ Age at diagnosis 4.45 2.16–9.15 <.0001 1.56 1.05–2.44 0.042
+ PV disease 4.65 2.24–9.65 <.0001 1.14 0.60–2.17 0.680
+ Cytoreduction + antiplatelet agents 5.26 2.47–11.2 <.0001 1.16 0.60–2.22 0.662
+ JAK2V617F homo 5.41 2.53–11.6 <.0001 1.11 0.58–2.15 0.750
OR odds ratio, CI confidence interval, p p value, PV polycythemia vera, ASA acetylsalicylic acid
aReference categories: hs-CRP <0.8 mg/L; PTX3 <4.8 ng/mL
The variables resulted statistically significant are reported in italicized style
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PTX3 and hs-CRP both reflect a condition of chronic
inflammation which is associated with the disease severity.
The strong association between the levels of PTX3
and the JAK2V617F allele burden is consistent with our
previous results [18] and considering the major role
played by JAK2V617F mutation in the pathogenesis of
inflammatory state in MPNs [10] is not surprising. In-
deed, it is well established that JAK2V617F determines a
more pronounced activation of platelets, leucocytes and
endothelial cells [10–12] and it might induce the accu-
mulation of reactive oxygen species in the haematopoi-
etic stem cell compartment [26], orchestrating the
construction of the inflammatory microenvironment of
MPNs [27]. The association of high PTX3 levels and
JAK2V617F homozygous status with haematological evo-
lution and all-cause mortality suggests that inflammation
in the tumour microenvironment might contribute to
the genetic instability and disease progression of MPNs
[15, 28]. Although it could be argued that only
hematological transformation in AML may be due to
additional mutation acquisition, the relative small num-
ber of total events prevented a formal evaluation of dif-
ferences by keeping a clear distinction between the MF
and AML evolution. In multivariate analysis, after ad-
justment for JAK2V617 allele burden, the association be-
tween PTX3 levels and adverse outcomes was no longer
statistically significant, suggesting that PTX3 levels
might simply reflect inflammation derived from consti-
tutively activated blood cells, belonging to the malignant
clone harbouring JAK2V617F mutation. A second rele-
vant finding, in keeping with our previous results [18],
was that the major thrombosis rate tended to be lower
at the highest PTX3 levels, suggesting that PTX3 might
have a protective role against the detrimental effects of
inflammation in the cardiovascular risk. Preclinical stud-
ies have shown that PTX3 is released from activated leu-
kocytes and attenuates neutrophil recruitment at sites of
inflammation [29], by limiting P-selectin-dependent in-
flammation [30]. Moreover, PTX3 deficiency was associ-
ated with increased fibrin deposition in different models
of tissue damage and a direct fibrinolytic effect of PTX3
has been described in vitro [31]. In addition, PTX3 ad-
ministration resulted to be protective in a model of ar-
terial thrombosis [32], and in carcinogenesis models, it
has been demonstrated that PTX3 acts as extrinsic
oncosupressor by regulating complement-mediated and
macrophage-sustained tumour inflammation [33]. While
it is possible that JAK2V617F mutation is a potent
driver of PTX3 release, the biologic and clinical cor-
relates that can be attributed to high levels of circu-
lating PTX3 remain to be defined and interpretations
are mostly speculative. In this regard, that PTX3
might play a role in disease progression and develop-
ment of fibrosis is a distinct possibility [34, 35].
In contrast to PTX3, hs-CRP levels were not associ-
ated with the JAK2V617F allele burden, supporting the
hypothesis that hs-CRP and PTX3 reflect distinct as-
pects of the inflammatory process and that different
mechanisms regulate the circulating levels of these pro-
teins. Patients with a more pronounced chronic inflam-
mation, as suggested by the high hs-CRP levels,
exhibited an increased risk of haematological evolution
and death of approximately three- and four fold, respect-
ively, and to a lower extent also of thrombotic events
compared to those in the lowest group. These findings
are in keeping with previous studies in apparently
healthy subjects, patients with cardiovascular disease
and MPNs patients overall showing that higher levels
hs-CRP are associated with an increased risk of all-cause
mortality, malignant diseases and thrombotic events [18,
19, 35–39]. A striking finding of our results is that the
magnitude of predictive capacity of adverse outcomes of
hs-CRP seems to be significantly greater in ET and PV
patients than in subjects with and without cardiovascu-
lar disease in whom the risk was only about 1.5-fold in-
creased in individuals with highest hs-CRP levels
compared to those with lowest levels [37, 40, 41].
We acknowledge that our study has some limitations.
First, PTX3 and hs-CRP were measured only once and
we could not account for intra-individual variations. In
this regard, future studies with prospective, repeated
evaluations of the two biomarkers will be necessary to
validate their predictive value for prognostic classifica-
tion. Second, biomarker measurements were not per-
formed at the time of diagnosis in many patients; thus,
we cannot ascertain whether elevated PTX-3 and hs-
CRP may represent sensitive markers of poor prognosis
since the diagnosis, or rather along with disease dur-
ation. However, this limitation does not negatively affect
the validity of established correlation between high levels
of PTX3 and JAK2V617F homozygous status, as well as
the prognostic relevance of both biomarkers, which re-
flect the main hypotheses of the current study. Finally,
the mechanisms by which PTX3 and hs-CRP are associ-
ated with adverse outcomes have not been addressed
and our data do not allow to distinguish between the
equally tenable explanations that the two biomarkers are
simply a marker or rather are mechanistic determinants
of patients’ total inflammatory burden. On the other
hand, the strength of this study is the high number of
well-characterized and molecularly annotated patients
that were evaluated with incident assessed outcomes.
Conclusions
The strong correlation between JAK2V617F allele burden
and PTX3 levels provides further evidence to support the
role of the JAK2V617F mutation as a key driver of the
MPN-associated chronic inflammation. These results may
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also represent the groundwork to perform prospective stud-
ies aimed at evaluating the impact of treatments targeting
simultaneously the clonal haematopoiesis (for example, with
interferon-alpha2) and the accompanying inflammatory
status (with agents such as JAK1/2 inhibitors, statins and
histone deacetylase inhibitors) on the risk of inflammation-
driven disease progression and cardiovascular events, espe-
cially in patients with high PTX3 and hs-CRP levels.
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